TP53 and glioblastoma: Remarkably, when romidepsin was combined with gamitrinib the reduction was further enhanced in a synergistic manner in both TP53 wild type U87 as well as mutated LN229 and U251 GBM cells, respectively (Figure 1B,D and Figure S1C,D).